抄録
Research and development (R&D) for medicines are extremely high risk. On the other hand, the R&D for blockbusters, which used be a main target for R&D of a pharmaceutical company, become difficult. The pharmaceutical company has to change R&D strategy from blockbusters to a lot of products. Therefore, the pharmaceutical company needs various technologies and it becomes almost impossible for it to own all technologies. The use of an open innovation, typically the industry-university cooperation, must be necessary for the solution of this problem, and the pharmaceutical company has to think about the appropriate IP strategy for the open innovation. And the government must make the industrial policy, which can make the pharmaceutical company to use an open innovation, including the proper IP protection for an invention relating a basic technology and the maintenance of the infrastructure promoting the industrial use of such a basic technology. Moreover, the emerging and developing markets, where the growth rate of the market for medicines are much higher than the developed country, becomes attractive. The pharmaceutical company should positively develop the business in these countries. However, the intellectual property system is not high level in these countries. The intellectual property, especially the patent, is very important for the business of the pharmaceutical company. The global harmonization of IP systems at a high level is desirable. It is necessary for global business of the pharmaceutical company to establish the IP system globally harmonized at a high level by the economic partnership agreement using the bilateral or multilateral negotiation.
